LLM 2021 | Evolution in myeloma therapy
Mark Bustoros
• 14 Oct 2021
An increased understanding of the pathobiology of multiple myeloma has transformed the treatment landscape with the regulatory approval of several novel agents. Mark Bustoros, MD, Weill Cornell Medicine, New York, NY, highlights CAR T-cell therapy, which is evolving rapidly in the myeloma field, and BCMA-targeted therapy, either bispecific antibodies or antibody-drug conjugates. Although the treatments currently available have transformed the treatment paradigm, research continues to focus on developing novel drugs targeting specific vulnerabilities in myeloma to tackle progression and relapses. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
